24-02-2026
Gaudium IVF IPO Day 3 update as subscription reaches 3.63 times with latest GMP trends
The GMP of Gaudium IVF & Women Health IPO has declined to ₹5, according to grey market sources. This suggests the shares are currently trading at a ₹5 premium over the issue price in the unofficial market. The drop in GMP reflects softer grey market sentiment compared to earlier levels. Investors are closely watching subscription trends and overall market conditions ahead of listing.
Gaudium IVF & Women Health IPO, which opened on February 20, was subscribed 3.63 times by the close of bidding on February 24, with strong participation from retail and non-institutional investors. The retail portion was subscribed 4.64 times and the NII segment 6.11 times, while QIB participation remained modest at 3%. The ₹165-crore issue, priced at ₹75–79 per share with a lot size of 189 shares, comprises a fresh issue of ₹90 crore and an OFS of ₹75 crore. The IPO allotment is expected on February 25, and listing is scheduled for February 27 on the BSE and NSE. The grey market premium has moderated to ₹5, indicating an estimated listing price of around ₹84, or a 6% premium over the upper band. The proceeds will be used for setting up new IVF centres, debt repayment, and general corporate purposes. Founded in 2009, the company operates over 30 fertility centres across India and reported strong FY25 growth, with PAT rising sharply and margins remaining healthy.